Primary Care Physicians’ Perspective on SGLT2 Inhibitors for Chronic Kidney Disease

Singapore has the second-highest per capita prevalence of chronic kidney disease (CKD) in the world (11.4%).1 Sodium/glucose cotransporter 2 inhibitors (SGLT2is) have shown significant efficacy at delaying CKD progression and reducing cardiovascular mortality in patients.2 Despite being available to primary care in 2017, recommended by local guidelines since 2022, and further subsidized starting in 2023, SGLT2i prescription rates in Singapore still indicate underprescription.3 Although a study identified factors affecting SGLT2i underprescription in CKD patients,4 its global extent remains unknown.